UNSPSC 51433904: Niguldipine

This classification denotes a calcium channel blocker with the molecular formula C36H39N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z81N45O25Z, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(4,4-diphenyl-1-piperidinyl)propyl methyl ester but generally known as niguldipine, which bears US NIH Compound Identifier 1236. European Medicines Agency schedules Niguldipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09284MIG.

UNSPSC 51433904 Niguldipine is a Commodity code representing a single pharmaceutical product line. State and local governments buy this medication—a calcium channel blocker used in emergency medical and hospital settings—as part of broader advanced life support and pharmaceutical procurement programs. Recent solicitations show demand driven by emergency medical services (fire rescue departments), state health agencies, and multistate cooperative purchasing alliances managing pharmacy benefit programs for state and local facilities. The work consists of supplying pharmaceuticals to specification, maintaining strict expiration dating and shelf-life requirements (typically nine months or more from acceptance), arranging timely delivery and replacement of expired stock, and compliance with FDA regulations, cGMP standards, and OSHA Hazard Communication Standards including Safety Data Sheets.

Activity appears concentrated in fire rescue and state health procurement. The City of Tampa's Purchasing Department solicited advanced life support medications (including labetalol, epinephrine, adenosine, and diltiazem) via IFB 26P00188 for Tampa Fire Rescue in Hillsborough County with an April 8, 2026 response deadline and estimated contract value of $40,000, including a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, due March 26, 2026, requiring vendors to supply through three authorized wholesalers (Cencara, Cardinal Health, Morris & Dickson). The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling future state-level procurement activity. Geographic spread spans Florida, Texas, and the upper Midwest, with activity driven by both individual municipalities and multistate cooperative vehicles.